$4.38
3.06% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

C4 Therapeutics Inc Target price 2024 - Analyst rating & recommendation

C4 Therapeutics Inc Classifications & Recommendation:

Buy
56%
Hold
44%

C4 Therapeutics Inc Price Target

Target Price $13.78
Price $4.38
Potential
Number of Estimates 9
9 Analysts have issued a price target C4 Therapeutics Inc 2025 . The average C4 Therapeutics Inc target price is $13.78. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 5 Analysts recommend C4 Therapeutics Inc to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the C4 Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the C4 Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 20.76 35.84
33.25% 72.63%
EBITDA Margin -632.42% -274.77%
61.27% 56.55%
Net Margin -907.49% -287.45%
52.67% 68.32%

8 Analysts have issued a sales forecast C4 Therapeutics Inc 2024 . The average C4 Therapeutics Inc sales estimate is

$35.8m
Unlock
. This is
6.44% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$40.4m 19.99%
Unlock
, the lowest is
$30.4m 9.71%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $20.8m 33.25%
2024
$35.8m 72.63%
Unlock
2025
$38.9m 8.51%
Unlock
2026
$22.5m 42.22%
Unlock
2027
$31.0m 37.96%
Unlock
2028
$177m 472.41%
Unlock

2 Analysts have issued an C4 Therapeutics Inc EBITDA forecast 2024. The average C4 Therapeutics Inc EBITDA estimate is

$-98.5m
Unlock
. This is
9.72% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-78.9m 27.62%
Unlock
, the lowest is
$-118m 8.18%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-131m 7.65%
2024
$-98.5m 24.99%
Unlock
2025
$-146m 48.17%
Unlock
2026
$-165m 12.86%
Unlock

EBITDA Margin

2023 -632.42% 61.27%
2024
-274.77% 56.55%
Unlock
2025
-375.18% 36.54%
Unlock
2026
-732.91% 95.35%
Unlock

2 C4 Therapeutics Inc Analysts have issued a net profit forecast 2024. The average C4 Therapeutics Inc net profit estimate is

$-103m
Unlock
. This is
14.12% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-102m 15.29%
Unlock
, the lowest is
$-104m 12.94%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-188m 1.91%
2024
$-103m 45.32%
Unlock
2025
$-116m 13.01%
Unlock
2026
$-96.7m 16.96%
Unlock

Net Margin

2023 -907.49% 52.67%
2024
-287.45% 68.32%
Unlock
2025
-299.37% 4.15%
Unlock
2026
-430.23% 43.71%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.67 -1.46
1.91% 45.32%
P/E negative
EV/Sales 3.37

2 Analysts have issued a C4 Therapeutics Inc forecast for earnings per share. The average C4 Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.46
Unlock
. This is
14.12% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.44 15.29%
Unlock
, the lowest is
$-1.48 12.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.67 1.91%
2024
$-1.46 45.32%
Unlock
2025
$-1.65 13.01%
Unlock
2026
$-1.37 16.97%
Unlock

P/E ratio

Current -2.57 358.93%
2024
-3.00 16.73%
Unlock
2025
-2.65 11.67%
Unlock
2026
-3.20 20.75%
Unlock

Based on analysts' sales estimates for 2024, the C4 Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.58 205.60%
2024
3.37 5.97%
Unlock
2025
3.10 7.85%
Unlock
2026
5.37 73.09%
Unlock
2027
3.89 27.52%
Unlock
2028
0.68 82.53%
Unlock

P/S ratio

Current 9.18 147.83%
2024
8.63 6.05%
Unlock
2025
7.95 7.84%
Unlock
2026
13.76 73.08%
Unlock
2027
9.97 27.51%
Unlock
2028
1.74 82.53%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today